Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory

NCT01456013 is registered in ClinicalTrials.gov with CardioRenal Systems, Inc. as lead sponsor.

NCT NCT01456013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01456013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate RenalGuard® System Safety & Efficacy When Compared With Standard Care in the Prevention of Contrast Induced NephRopathy in the SettinG of a Catheterization Laboratory
Lead sponsor
CardioRenal Systems, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
January 31, 2012
Completion date
December 31, 2024
Enrollment
326 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

contrast induced nephropathy